AI & ChatGPT searches , social queries for SIPULEUCEL T
Search references for SIPULEUCEL T. Phrases containing SIPULEUCEL T
See searches and references containing SIPULEUCEL T!
Search references for SIPULEUCEL T. Phrases containing SIPULEUCEL T
See searches and references containing SIPULEUCEL T!SIPULEUCEL T
Medication
Sipuleucel-T, sold under the brand name Provenge, developed by Dendreon Pharmaceuticals, LLC, is a cell-based cancer immunotherapy for prostate cancer
Sipuleucel-T
Activation or suppression of the immune system to treat disease
The first FDA-approved cell-based immunotherapy, the cancer vaccine Sipuleucel-T is one example of this approach. The Immune Response Corporation (IRC)
Immunotherapy
hypertension, diabetes, cancer, or autoimmune disease.[citation needed] Sipuleucel-T is the first DCs- based cancer vaccine for men with asymptomatic or minimally
Dendritic cell-based cancer vaccine
Dendritic_cell-based_cancer_vaccine
Artificial stimulation of the immune system to treat cancer
Currently, only one vaccine (sipuleucel-T for prostate cancer) has been approved. In cell-mediated therapies like CAR-T cell therapy, immune cells are
Cancer_immunotherapy
Vaccine that either treats existing cancer or prevents development of cancer
after the vaccine is delivered. The best known dendritic cell vaccine is Sipuleucel-T (Provenge), which only improved survival by four months. The efficacy
Cancer_vaccine
Immunotherapeutic company founded by Jonas Salk and Kevin Kimberlin
that invention, Sipuleucel-T, more commonly known as Provenge, became the first FDA-approved immunotherapeutic cancer vaccine. Sipuleucel-T, initially approved
The Immune Response Corporation
The_Immune_Response_Corporation
Biotechnology company
biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer. It consists of a mixture of
Dendreon
Medical researcher
also served as the lead investigator for Dendreon's clinical trials for Sipuleucel-T, a therapeutic vaccine for prostate cancer approved in 2010. After 28
Philip_Kantoff
Vaccination received after infection
which are approved by USA Food and Drug Administration: Provenge is Sipuleucel-T, a dendritic cell based vaccine for prostate cancer. Bacillus Calmettle-Guerin
Therapeutic_vaccines
American businessman
pp. 432. ISBN 9780199334414. immune response corporation kimberlin. "Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine". Drugs in R&D. 7 (3): 197–201
Kevin_Kimberlin
Taking measures to decrease cancer incidence
released or are undergoing clinical trial. FDA-approved vaccines, such as Sipuleucel-T for metastasizing prostate cancer or Nivolumab for melanoma and lung
Cancer_prevention
Male reproductive organ cancer
inhibitor abiraterone acetate. An alternative is the cell therapy procedure Sipuleucel-T, where the affected person's immune cells are removed, treated to more
Prostate_cancer
Procedure separating white blood cells from blood
O, Salama A. Kantoff P.W., Higano C.S., Shore N.D.; et al. (2010). "Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer". N Engl J Med
Leukapheresis
topotecan for chemotherapy of cancer 2010 – US FDA approves immunotherapy, sipuleucel-T dendritic cell vaccine for advanced prostate cancer 2010 – China advances
Timeline of cancer treatment development
Timeline_of_cancer_treatment_development
Medical intervention
research for a number of tumors, notably melanoma and renal cell carcinoma. Sipuleucel-T is a vaccine-like strategy for prostate cancer in which dendritic cells
Cancer_treatment
Research into causes and treatment of cancer
of cancer treatment research include: Anti-cancer vaccines Oncophage Sipuleucel-T (Provenge) is a prostate cancer vaccine Inactivated tumor cells are investigated
Cancer_research
Pharmaceutical drug classification
L03AX15 Mifamurtide L03AX16 Plerixafor L03AX17 Sipuleucel-T L03AX18 Cridanimod L03AX19 Dasiprotimut-T L03AX21 Elapegademase L03AX22 Leniolisib L03AX23
ATC_code_L03
American urologist
Evaluate Sipuleucel-T Manufactured with Different Concentrations of PA2024 Antigen (P07-2). GCO 09–1509. An open label study of sipuleucel-T in men with
Michael_Palese
Chemical compound
PMC 10355925. PMID 26024831. S2CID 10625154. Slovin SF (29 September 2015). "Sipuleucel-T - A Model for Immunotherapy Trial Development". In Mydlo JH, Godec CJ
Flutamide
American urologist
Men with Metastatic Androgen Independent Prostate Cancer to Evaluate Sipuleucel-T Manufactured with Different Concentrations of PA2024 Antigen (P07-2)
Simon_J._Hall
sipavibart (INN) siplizumab (INN) sipoglitazar (INN) siponimod (INN) sipuleucel-T (USAN) siratiazem (INN) sirolimus (INN) sirukumab (INN) sisomicin (INN)
List_of_drugs:_Si
American physician
in April 2009 and is supported by Cougar Biotechnology. A Registry of Sipuleucel-T Therapy in men with advanced prostate Cancer. The study began in June
Nicholas_J._Vogelzang
Therapeutic cancer vaccine in development
Responses for the 2010 PLI at Dendreon's Manufacturing Facility for Sipuleucel-T at Morris Plains, New Jersey - Provenge". U.S. Food and Drug Administration
Neuvenge
SIPULEUCEL T
SIPULEUCEL T
SIPULEUCEL T
SIPULEUCEL T
SIPULEUCEL T
SIPULEUCEL T
SIPULEUCEL T
SIPULEUCEL T
SIPULEUCEL T